A Merck manufacturing site in Ireland that was slated to close has been saved by the drugmaker’s hot-selling cancer drug Keytruda.
Merck & Co. today said it will build a new biologics plant at its Swords site near Dublin to produce the blockbuster immuno-oncology therapy. It didn’t disclose the size of the investment but said it would create 350 jobs as part of the deal.
The site was slated to be closed or sold last year. The company, known as MSD outside the U.S., is shooting to have the new facility operational by 2021 and producing commercial products the next year, a goal the company understands is aggressive, a spokeswoman said in an email, confirming reports in Irish media.
“It’s a bold statement by MSD, but that’s our target,” Ger Brennan, managing director of MSD Human Health, told The Irish Times.
He told the newspaper that Merck needed to have confidence in its supply chain since it expects significant growth in immuno-oncology.
Keytruda, which has racked up an impressive list of approvals for different cancers since its 2014 approval, is producing significant growth on its own. The PD-L1 targeted drug contributed almost 10% of Merck’s sales last year, $3.8 billion out of Merck’s $40.1 billion total. The drug posted a 172% increase year over year as it added multiple approvals, including three last May for front-line lung cancer, bladder cancer and microsatellite instability-high cancer. Weeks later, it followed up with a win in two types of recurrent or advanced gastric cancer.
The Swords site where the new plant will be built is near Dublin. Merck produced women’s health products at the facility but in 2013 added it to a list of facilities it was closing in a manufacturing and cost-cutting slim-down and moved production to the Netherlands. At the time, the facility had 570 jobs which it said would be whittled down until the site was sold or closed in 2017.
It put the 33-acre site up for sale last year for about $30 million, but Brennan told The Irish Times that when it projected Merck would need more Keytruda production capacity, the site came into consideration. The fact that infrastructure was in place and its history as a pharma site would speed planning gave it an edge for the new plant.
When Merck reported full-year earnings this month, the drugmaker said it would use some of the repatriated profits it would have as a result of U.S. tax reform on a $12 billion capital projects splurge over the next five years. While about $8 billion is slated for U.S. projects, the new biologics plant and 350 jobs slated in Ireland, is the first of those projects to be announced.
By Eric Palmer
Source: Fierce Pharma
The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).
“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”
The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.
